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Dear Editor,
A 57-year-old man was admitted to our hospital with acute
lower abdominal pain and diarrhoea. The patient had been
diagnosed with a CD20 and bcr-abl positive B-cell acute
lymphoblastic leukaemia 15 months ago and was treated
with four cycles rituximab-Hyper-CVAD. He was healthy
with a complete molecular remission at his last routine
examination 4 weeks ago.
A CT scan of the abdomen revealed colitis of the colon
descendens with perifocal oedema. Antibacterial therapy
with piperazillin/tazobactam was initiated resulting in a
normalisation of the initially elevated inflammatory blood
markers. In contrast, the abdominal pain worsened although
the analgesic therapy was substantially intensified. Due to
increased pain, the patient’s oral food intake was poor.
Additionally, he developed tachycardia, hypertension as
well as episodes with aggressiveness and loss of orienta-
tion. Further investigations, including extensive blood and
bacterial stool analysis as well as a gastro- and colono-
scopy, were unremarkable except for the urine, which
turned from a clear yellow to a dark red colour (Fig. 1),
highly suggestive for an acute porphyria. Indeed, increased
levels of δ-aminolevulinic acid and porphobilinogen were
found in the urine. All porphyrinogenic drugs were halted,
an adequate caloric intake was guaranteed by nasogastric
feeding and the patient was treated with exogenous heme-
arginate for 4 days. The patient recovered completely from
his symptoms within a few days and was discharged after
2 weeks of hospitalisation. A molecular analysis was
positive for the presence of the W283X-mutation in the
porphobilinogen deaminase gene, a common mutation in
Swiss residents with acute intermittent porphyria (AIP). He
was completely asymptomatic when last seen in April 2009.
AIP is an autosomal-dominant inherited disease of the
heme biosynthetic pathway with a prevalence of symptom-
atic disease of one to two per 100,000 [1]. In AIP, the
activity of the porphobilinogen deaminase (PBG) is
reduced, resulting in an accumulation of upstream porphy-
rin precursors δ-aminolevulinic acid and porphobilinogen.
At the moment, over 250 mutations in the PBG gene are
known. Nearly 60% of all Swiss patients with an AIP carry
the nonsense mutation W283X [2]. The majority of the
mutation carriers are clinically healthy and exhibit symp-
toms only in situations when precipitating factors are
present [3]. These include various drugs, poor energy
intake during fasting as well as stress from illness and
fever. Under these circumstances, the heme biosynthetic
pathway gets activated and results in an excess accumula-
tion of the porphyrin precursors δ-aminolevulinic acid and
porphobilinogen due to the PGB enzyme deficiency. The
key issues for acute therapy are to avoid drugs known to be
porphyrinogenic, to promptly treat infections and to
maintain an adequate caloric intake. Furthermore, intrave-
nous heme derivates supporting the increased heme demand
are the most effective treatment modalities for acute
porphyria attacks [4].
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It is interesting to realise that this patient was treated by
an intensive chemotherapy regimen without the develop-
ment of any symptoms. Currently, he is under maintenance
treatment with dasatinib, a novel bcr-abl tyrosine kinase
inhibitor, from which it is not yet known if it is tolerated by
patients with acute porphyria.
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